Ads
related to: what is zanubrutinib used for- Possible Side Effects
Visit Site To See Possible Side
Effects & Safety Information.
- Dosing Schedule
Read About Dosing Schedules, Dosing
Modifications & Safety Information.
- Patient Care Guide
Learn About Resources For Your
Patients & Request A Care Guide.
- Clinical Trial Data
Read About Efficacy & Safety For An
HCC Treatment On Official HCP Site.
- Study Design Info
Visit HCP Site To Read About Study
Design & Safety On HCC Treatment.
- Learn More About HCC
Find Info For HCPs About HCC
Treatment, Safety, & Efficacy.
- Possible Side Effects
Search results
Results From The WOW.Com Content Network
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
BeiGene also developed zanubrutinib, a Bruton's tyrosine kinase inhibitor for the treatment of cancer, from a formula its scientists created in Beijing in 2012. [17] In November 2019, zanubrutinib became the first cancer drug developed in China to gain FDA approval; [ 18 ] it received accelerated approval for the treatment of mantle cell ...
Zenocutuzumab was approved for medical use in the United States in December 2024. [3] [4] [5] It is the first approval by the US Food and Drug Administration (FDA) of a systemic therapy for people with non-small cell lung cancer or pancreatic adenocarcinoma harboring an neuregulin 1 gene fusion. [3] The FDA considers it to be a first-in-class ...
Ibritumomab tiuxetan is used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (NHL), a lymphoproliferative disorder, and previously untreated follicular NHL in adults who achieve a partial or complete response to first-line chemotherapy. [5] The treatment starts with an infusion of rituximab.
Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma. [1] [2] [4] It inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK). [5]
Ads
related to: what is zanubrutinib used for